
CURIS
Curis Lifesciences Limited
- IPO Status
- Closed
- Open Date
- 7 Nov 2025
- Close Date
- 11 Nov 2025
IPO Details
- Min. Investment
- ₹2,56,000
- Price Band
- ₹120 - ₹128
- Lot Size
- 1000 shares
- Issue Size
- ₹28 Cr
- Face Value
- 10
- IPO Doc
- —
Schedule
- IPO open7 Nov 2025
- IPO close date11 Nov 2025
- Allotment date12 Nov 2025
- Funds unblock or debit13 Nov 2025
- Listing date14 Nov 2025
Financial Performance
- Revenue
- Profit
Stocks similar to CURIS
- Sotac Pharmaceuticals Limited
- Lincoln Pharmaceuticals Limited
FAQs
Curis Lifesciences Limited IPO is a SME IPO aggregating up to ₹28 Cr, with equity shares of face value ₹10 each. The shares are proposed to be listed on NSE.
The Curis Lifesciences Limited IPO opened on 7 Nov 2025 and closed on 11 Nov 2025. IPO Period: 7 Nov 2025 – 11 Nov 2025.
The price band for the Curis Lifesciences Limited IPO is ₹120 to ₹128 per share. Investors can bid within the specified price band, subject to the applicable IPO rules.
The minimum lot size is 1,000 shares. At the upper price band of ₹128, the minimum investment required is ₹2,56,000.
Particular Details Lot Size 1,000 shares Minimum Application 2,000 shares Price Band ₹120 – ₹128 Minimum Investment ₹2,56,000 Here is the timeline for the Curis Lifesciences Limited IPO:
IPO Event Date IPO Opens 7 Nov 2025 IPO Closes 11 Nov 2025 UPI Mandate Deadline 11 Nov 2025, 5:00 PM Basis of Allotment 12 Nov 2025 Refund Initiation 13 Nov 2025 Shares Credited 13 Nov 2025 Listing Date 14 Nov 2025 The basis of allotment for the Curis Lifesciences Limited IPO is expected to be finalised on 12 Nov 2025. Investors can check their allotment status through the registrar or relevant stock exchange website using their application details. Registrar: Link Intime.
The equity shares of Curis Lifesciences Limited are proposed to be listed on NSE. Proposed Listing Date: 14 Nov 2025.
The key financial performance of Curis Lifesciences Limited is:
Financial Year Revenue Profit FY24 ₹35.56 Cr ₹4.87 Cr FY25 ₹50.26 Cr ₹6.21 Cr FY26 ₹60.63 Cr ₹6.92 Cr Revenue CAGR: 30.6% | Profit CAGR: 19.2%. Figures are as disclosed in the company's offer documents.


